尼日利亚乔斯一组有动脉粥样硬化性心血管疾病风险的患者的抗血小板能力

Basil N. Okeahialam, Emmanuel Akor, G. Shut, Ogo Ifeacho, Bangalu Dauda, Anil Sirisena, G. Amusa
{"title":"尼日利亚乔斯一组有动脉粥样硬化性心血管疾病风险的患者的抗血小板能力","authors":"Basil N. Okeahialam, Emmanuel Akor, G. Shut, Ogo Ifeacho, Bangalu Dauda, Anil Sirisena, G. Amusa","doi":"10.25259/jhas_13_2023","DOIUrl":null,"url":null,"abstract":"\n\nPatients with atherosclerotic cardiovascular diseases (ASCVDs) are predisposed to atherothrombosis and ischemic phenomena. Antiplatelets mitigate this but not consistently, as these ischemic events still occur despite their administration. This is called antiplatelet resistance. We sought to see how much of this occurs in our patients since its rate is bound to differ from place to place. The burden of antiplatelet resistance has not been determined in our environment.\n\n\n\nPatients at risk of ASCVD who were receiving antiplatelet treatments were invited to participate in this study. They were enrolled first into a two week wash out phase, after which baseline aggregometry and full blood count were done. They were then given either Aspirin or Clopidogrel for four weeks and had the same blood work-up repeated. The Aggregometer was used to determine the platelet aggregability at these different times. If the second set showed >10% reduction from baseline, such patients were adjudged sensitive. A reduction <10% of the first value defined resistance.\n\n\n\nTwenty patients (15 F/5 M) were in Group 1 and received a low dose of Aspirin (75 mg), the age range of 42–76 years, with a mean (standard deviation [SD]) of 60.75 (10.45). Twenty-six were in Group 2 (18 F/8 M) and received low dose clopidogrel (75 mg), with an age range of 23–87 years and a mean (SD) of 58.08 (14.18). Fifteen (75%) were sensitive in Group 1 (Aspirin) with 25% resistant. For Clopidogrel, 14 (53.85%) were sensitive and 12 (46.15%) resistant. In a few cases, the aggregability actually increased paradoxically on treatment.\n\n\n\nAntiplatelet resistance also occurs in our environment; it is worse for Clopidogrel than for Aspirin. These are people who, despite being on antiplatelets, would go on to develop these atherothrombotic ischemic phenomena. Efforts to identify the predictors of this phenomenon of resistance and work out effective counteractions should be encouraged.\n","PeriodicalId":499735,"journal":{"name":"Journal of Hematology and Allied Sciences","volume":"18 3‐4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Antiplatelet resistance among a cohort of patients at risk of atherosclerotic cardiovascular diseases in Jos, Nigeria\",\"authors\":\"Basil N. Okeahialam, Emmanuel Akor, G. Shut, Ogo Ifeacho, Bangalu Dauda, Anil Sirisena, G. Amusa\",\"doi\":\"10.25259/jhas_13_2023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nPatients with atherosclerotic cardiovascular diseases (ASCVDs) are predisposed to atherothrombosis and ischemic phenomena. Antiplatelets mitigate this but not consistently, as these ischemic events still occur despite their administration. This is called antiplatelet resistance. We sought to see how much of this occurs in our patients since its rate is bound to differ from place to place. The burden of antiplatelet resistance has not been determined in our environment.\\n\\n\\n\\nPatients at risk of ASCVD who were receiving antiplatelet treatments were invited to participate in this study. They were enrolled first into a two week wash out phase, after which baseline aggregometry and full blood count were done. They were then given either Aspirin or Clopidogrel for four weeks and had the same blood work-up repeated. The Aggregometer was used to determine the platelet aggregability at these different times. If the second set showed >10% reduction from baseline, such patients were adjudged sensitive. A reduction <10% of the first value defined resistance.\\n\\n\\n\\nTwenty patients (15 F/5 M) were in Group 1 and received a low dose of Aspirin (75 mg), the age range of 42–76 years, with a mean (standard deviation [SD]) of 60.75 (10.45). Twenty-six were in Group 2 (18 F/8 M) and received low dose clopidogrel (75 mg), with an age range of 23–87 years and a mean (SD) of 58.08 (14.18). Fifteen (75%) were sensitive in Group 1 (Aspirin) with 25% resistant. For Clopidogrel, 14 (53.85%) were sensitive and 12 (46.15%) resistant. In a few cases, the aggregability actually increased paradoxically on treatment.\\n\\n\\n\\nAntiplatelet resistance also occurs in our environment; it is worse for Clopidogrel than for Aspirin. These are people who, despite being on antiplatelets, would go on to develop these atherothrombotic ischemic phenomena. Efforts to identify the predictors of this phenomenon of resistance and work out effective counteractions should be encouraged.\\n\",\"PeriodicalId\":499735,\"journal\":{\"name\":\"Journal of Hematology and Allied Sciences\",\"volume\":\"18 3‐4\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Hematology and Allied Sciences\",\"FirstCategoryId\":\"0\",\"ListUrlMain\":\"https://doi.org/10.25259/jhas_13_2023\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hematology and Allied Sciences","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.25259/jhas_13_2023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

动脉粥样硬化性心血管疾病(ASCVDs)患者容易发生动脉粥样硬化血栓形成和缺血现象。抗血小板药物可减轻这种情况,但并不能持续缓解,因为尽管服用了抗血小板药物,这些缺血性事件仍会发生。这就是所谓的抗血小板抵抗。我们试图了解这种情况在患者中的发生率,因为其发生率必然因地而异。正在接受抗血小板治疗的 ASCVD 高危患者受邀参加这项研究。他们首先进入为期两周的冲洗阶段,然后进行基线聚集测定和全血细胞计数。然后,他们接受为期四周的阿司匹林或氯吡格雷治疗,并重复同样的血液检查。在这些不同的时间段,使用聚集测定仪测定血小板聚集性。如果第二组数据显示比基线降低>10%,则此类患者被判定为敏感患者。第 1 组有 20 名患者(15 名女性/5 名男性),接受小剂量阿司匹林(75 毫克)治疗,年龄在 42-76 岁之间,平均(标准差 [SD])为 60.75(10.45)岁。第 2 组 26 人(18 名女性/8 名男性)接受低剂量氯吡格雷(75 毫克)治疗,年龄在 23-87 岁之间,平均(标准差[SD])为 58.08(14.18)。第一组(阿司匹林)中有 15 人(75%)对阿司匹林敏感,25%的人对阿司匹林耐药。对于氯吡格雷,14 例(53.85%)敏感,12 例(46.15%)耐药。在我们的环境中,抗血小板药物耐药性也时有发生;氯吡格雷的耐药性比阿司匹林更严重。这些人尽管服用了抗血小板药物,但仍会出现这些动脉粥样血栓性缺血现象。应鼓励努力找出这种抗药性现象的预测因素,并制定有效的应对措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Antiplatelet resistance among a cohort of patients at risk of atherosclerotic cardiovascular diseases in Jos, Nigeria
Patients with atherosclerotic cardiovascular diseases (ASCVDs) are predisposed to atherothrombosis and ischemic phenomena. Antiplatelets mitigate this but not consistently, as these ischemic events still occur despite their administration. This is called antiplatelet resistance. We sought to see how much of this occurs in our patients since its rate is bound to differ from place to place. The burden of antiplatelet resistance has not been determined in our environment. Patients at risk of ASCVD who were receiving antiplatelet treatments were invited to participate in this study. They were enrolled first into a two week wash out phase, after which baseline aggregometry and full blood count were done. They were then given either Aspirin or Clopidogrel for four weeks and had the same blood work-up repeated. The Aggregometer was used to determine the platelet aggregability at these different times. If the second set showed >10% reduction from baseline, such patients were adjudged sensitive. A reduction <10% of the first value defined resistance. Twenty patients (15 F/5 M) were in Group 1 and received a low dose of Aspirin (75 mg), the age range of 42–76 years, with a mean (standard deviation [SD]) of 60.75 (10.45). Twenty-six were in Group 2 (18 F/8 M) and received low dose clopidogrel (75 mg), with an age range of 23–87 years and a mean (SD) of 58.08 (14.18). Fifteen (75%) were sensitive in Group 1 (Aspirin) with 25% resistant. For Clopidogrel, 14 (53.85%) were sensitive and 12 (46.15%) resistant. In a few cases, the aggregability actually increased paradoxically on treatment. Antiplatelet resistance also occurs in our environment; it is worse for Clopidogrel than for Aspirin. These are people who, despite being on antiplatelets, would go on to develop these atherothrombotic ischemic phenomena. Efforts to identify the predictors of this phenomenon of resistance and work out effective counteractions should be encouraged.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信